Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	negative regulation of transcription by RNA polymerase III	SETD5 NAB2	1.98e-05	4	38	2	GO:0016480
GeneOntologyBiologicalProcess	PML body organization	HABP4 PML	1.18e-04	9	38	2	GO:0030578
GeneOntologyBiologicalProcess	negative regulation of DNA-templated transcription	GON4L POU1F1 ZNF131 PDE2A ZNF22 SETD5 KMT5A IFT172 NAB2 PML	1.63e-04	1399	38	10	GO:0045892
GeneOntologyBiologicalProcess	negative regulation of RNA biosynthetic process	GON4L POU1F1 ZNF131 PDE2A ZNF22 SETD5 KMT5A IFT172 NAB2 PML	1.77e-04	1413	38	10	GO:1902679
GeneOntologyBiologicalProcess	cilium organization	DNAAF2 FAM161B SCLT1 IFT172 DNAH17 SEPTIN2	2.16e-04	476	38	6	GO:0044782
GeneOntologyCellularComponent	septin complex	SEPTIN3 SEPTIN2	3.04e-04	14	39	2	GO:0031105
GeneOntologyCellularComponent	septin ring	SEPTIN3 SEPTIN2	3.04e-04	14	39	2	GO:0005940
GeneOntologyCellularComponent	septin cytoskeleton	SEPTIN3 SEPTIN2	4.00e-04	16	39	2	GO:0032156
Domain	Septin	SEPTIN3 SEPTIN2	2.63e-04	13	35	2	PF00735
Domain	G_SEPTIN_dom	SEPTIN3 SEPTIN2	2.63e-04	13	35	2	IPR030379
Domain	G_SEPTIN	SEPTIN3 SEPTIN2	2.63e-04	13	35	2	PS51719
Domain	Septin	SEPTIN3 SEPTIN2	3.06e-04	14	35	2	IPR016491
Domain	SET	SETD5 KMT5A	2.67e-03	41	35	2	PF00856
Domain	SET	SETD5 KMT5A	3.35e-03	46	35	2	SM00317
Domain	SET_dom	SETD5 KMT5A	3.95e-03	50	35	2	IPR001214
Domain	SET	SETD5 KMT5A	3.95e-03	50	35	2	PS50280
Domain	RhoGAP	ARHGAP30 ARHGAP11A	6.01e-03	62	35	2	SM00324
Domain	RhoGAP	ARHGAP30 ARHGAP11A	6.20e-03	63	35	2	PF00620
Domain	RHOGAP	ARHGAP30 ARHGAP11A	6.39e-03	64	35	2	PS50238
Domain	RhoGAP_dom	ARHGAP30 ARHGAP11A	6.39e-03	64	35	2	IPR000198
Domain	-	ARHGAP30 ARHGAP11A	6.39e-03	64	35	2	1.10.555.10
Domain	Rho_GTPase_activation_prot	ARHGAP30 ARHGAP11A	1.18e-02	88	35	2	IPR008936
Domain	WD40	THOC3 EML3 IFT172	1.24e-02	259	35	3	PF00400
Pubmed	In silico docking of forchlorfenuron (FCF) to septins suggests that FCF interferes with GTP binding.	SEPTIN3 SEPTIN2	1.29e-06	2	40	2	24787956
Pubmed	Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics.	UNC45A IFT172 DNAH17	1.58e-06	20	40	3	21689717
Pubmed	Molecular Recognition at Septin Interfaces: The Switches Hold the Key.	SEPTIN3 SEPTIN2	7.73e-06	4	40	2	32910969
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	APBA1 PDE2A EIF3C SEPTIN3 LEO1 TRIO IFT172 SIPA1L1 SEPTIN2	1.21e-05	1285	40	9	35914814
Pubmed	A draft of the human septin interactome.	SEPTIN3 SEPTIN2	1.29e-05	5	40	2	21082023
Pubmed	Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.	HABP4 TRIO IFT172 SIPA1L1 NUFIP2 SEPTIN2	1.63e-05	475	40	6	31040226
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	GON4L HABP4 EIF3C UNC45A SEPTIN3 THOC3 SETD5 SIPA1L1 NUFIP2	4.04e-05	1497	40	9	31527615
Pubmed	Superfluous role of mammalian septins 3 and 5 in neuronal development and synaptic transmission.	SEPTIN3 SEPTIN2	4.62e-05	9	40	2	18809578
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	UNC45A COL17A1 THOC3 ARHGAP11A SIPA1L1 PML NUFIP2 SEPTIN2	7.81e-05	1257	40	8	36526897
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	GON4L SETD5 IFT172 SIPA1L1 NUFIP2	1.01e-04	407	40	5	12693553
Pubmed	Setd5 is essential for mammalian development and the co-transcriptional regulation of histone acetylation.	LEO1 SETD5	1.16e-04	14	40	2	27864380
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	SEPTIN3 LEO1 SIPA1L1 SEPTIN2	1.44e-04	231	40	4	16452087
Pubmed	Localization of septin proteins in the mouse cochlea.	SEPTIN3 SEPTIN2	1.53e-04	16	40	2	22575789
Pubmed	Premature differentiation and aberrant movement of pituitary cells lacking both Hes1 and Prop1.	PCSK2 POU1F1	1.95e-04	18	40	2	18996108
Pubmed	Long-term potentiation modulates synaptic phosphorylation networks and reshapes the structure of the postsynaptic interactome.	PDE2A SEPTIN3 TRIO SEPTIN2	1.97e-04	251	40	4	27507650
Pubmed	A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex.	DNAAF2 ZNF131 DDX3Y TRIO PML	2.00e-04	472	40	5	38943005
Pubmed	Transcription-coupled nucleotide excision repair is coordinated by ubiquitin and SUMO in response to ultraviolet irradiation.	EIF3C LEO1 PML	2.24e-04	102	40	3	31722399
Pubmed	UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination.	DDX3Y HABP4 COL17A1 THOC3 SEPTIN2	2.41e-04	491	40	5	36273042
Pubmed	Hes1 is required for pituitary growth and melanotrope specification.	PCSK2 POU1F1	3.50e-04	24	40	2	17367776
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	UNC45A INPP5F TRIO SIPA1L1 PML CCDC18	4.23e-04	861	40	6	36931259
Pubmed	Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation.	GON4L ZNF131 HABP4 EIF3C INPP5F EML3 SEPTIN2	4.24e-04	1215	40	7	15146197
Pubmed	Vti1b promotes TRPV1 sensitization during inflammatory pain.	DDX3Y NUFIP2 SEPTIN2	4.26e-04	127	40	3	30335684
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	THOC3 SIPA1L1 PML NUFIP2 SEPTIN2	4.39e-04	560	40	5	21653829
Pubmed	Bardet-Biedl Syndrome Overview	SCLT1 IFT172	4.45e-04	27	40	2	20301537
Pubmed	Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.	DDX3Y ARHGAP30 NUFIP2	4.87e-04	133	40	3	15144186
Pubmed	Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.	RNF25 ZNF131 PML	5.42e-04	138	40	3	28786561
Pubmed	Identification and characterization of SAP25, a novel component of the mSin3 corepressor complex.	DDX3Y PML	5.50e-04	30	40	2	16449650
Pubmed	Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions.	ARHGAP30 ZNF22 UNC45A ARHGAP11A TRIO SEPTIN2	5.87e-04	916	40	6	32203420
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	ZNF131 EIF3C UNC45A PML NUFIP2 SEPTIN2	6.50e-04	934	40	6	33916271
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	NRG2 EIF3C SIPA1L1 NUFIP2	6.70e-04	347	40	4	17114649
Pubmed	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.	PCSK2 POU1F1 ZNF131	6.78e-04	149	40	3	25231870
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	PDE2A SEPTIN3 TRIO SIPA1L1 NUFIP2 SEPTIN2	7.62e-04	963	40	6	28671696
Pubmed	ZZW-115-dependent inhibition of NUPR1 nuclear translocation sensitizes cancer cells to genotoxic agents.	EIF3C THOC3 PML NUFIP2 SEPTIN2	9.21e-04	660	40	5	32780723
Pubmed	Defining the human deubiquitinating enzyme interaction landscape.	EIF3C UNC45A THOC3 SCLT1 SIPA1L1 NUFIP2	9.51e-04	1005	40	6	19615732
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	DDX3Y PDE2A EIF3C TRIO SIPA1L1 NUFIP2 SEPTIN2	1.11e-03	1431	40	7	37142655
Pubmed	Spatiotemporal-resolved protein networks profiling with photoactivation dependent proximity labeling.	THOC3 PML NUFIP2 SEPTIN2	1.13e-03	399	40	4	35987950
Pubmed	Insm1 controls development of pituitary endocrine cells and requires a SNAG domain for function and for recruitment of histone-modifying factors.	PCSK2 POU1F1	1.13e-03	43	40	2	24227653
GeneFamily	Septins	SEPTIN3 SEPTIN2	1.92e-04	13	29	2	732
GeneFamily	Rho GTPase activating proteins\|BCH domain containing	ARHGAP30 ARHGAP11A	2.90e-03	50	29	2	721
Coexpression	GSE16451_CTRL_VS_WEST_EQUINE_ENC_VIRUS_IMMATURE_NEURON_CELL_LINE_DN	DNAAF2 ZNF22 LEO1 KMT5A IFT172	1.30e-05	200	40	5	M7428
ToppCell	10x5'v1-week_14-16-Endothelial-stroma-immature_EC\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	PDE2A EIF3C PML SEPTIN2	2.50e-05	190	40	4	b8693567e26edb830482a60746bf3632a2bf058c
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_cycling-mes_proliferating2_(11)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	ARHGAP11A SCLT1 KMT5A CCDC18	2.55e-05	191	40	4	0ba5b112a82e489f5a21966f78a403a7436ce73b
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_cycling-mes_proliferating2_(11)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ARHGAP11A SCLT1 KMT5A CCDC18	2.60e-05	192	40	4	026f3e38970bea1e6e8d76a4e2becdfb8484b2ff
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-immature_mesenchymal_cell-cycling_stromal\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ARHGAP11A SCLT1 KMT5A CCDC18	2.77e-05	195	40	4	742c82c86487314cdb3178012004adb1164bcbdb
ToppCell	5'-GW_trimst-1-SmallIntestine-Mesenchymal-immature_mesenchymal_cell-cycling_stromal\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ARHGAP11A SCLT1 KMT5A CCDC18	2.94e-05	198	40	4	c3dd887c95587f930b7afd32385627a9fa029ca4
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Proliferating-cycling_dorsal_progenitors\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	ARHGAP11A SCLT1 KMT5A CCDC18	2.94e-05	198	40	4	5f0964c3aa7e1dc52cbb46e754078920b65bcb88
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Proliferating\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	ARHGAP11A SCLT1 KMT5A CCDC18	2.94e-05	198	40	4	629d674a9c9108c1acb3f7af57bbdbf34bb0528e
Drug	Altretamine [654-05-6]; Down 200; 19uM; MCF7; HT_HG-U133A	RNF25 UNC45A EML3 SIPA1L1 PML	2.20e-05	194	40	5	6467_DN
Drug	benserazide hydrochloride; Down 200; 10uM; SKMEL5; HG-U133A	GON4L HABP4 UNC45A TRIO PML	2.31e-05	196	40	5	631_DN
Drug	Hydroflumethiazide [135-09-1]; Up 200; 12uM; PC3; HT_HG-U133A	GON4L HABP4 UNC45A TRIO PML	2.37e-05	197	40	5	7259_UP
Drug	Levocabastine hydrochloride [79547-78-7]; Up 200; 8.8uM; PC3; HT_HG-U133A	HABP4 UNC45A ARHGAP11A EML3 PML	2.49e-05	199	40	5	7249_UP
Drug	Tacrine hydrochloride hydrate [1684-40-8]; Up 200; 15.8uM; MCF7; HT_HG-U133A	APBA1 NRG2 GON4L HABP4 PML	2.55e-05	200	40	5	2633_UP
Drug	Antigens, Polyomavirus Transforming	GON4L ZNF131 ATP11C HABP4 THOC3 ARHGAP11A SCLT1	1.46e-04	668	40	7	ctd:D000952
Drug	Metaproterenol sulfate, orciprenaline sulfate [5874-97-5]; Up 200; 7.6uM; HL60; HT_HG-U133A	RNF25 DDX3Y SIPA1L1 DNAH17	2.48e-04	175	40	4	2485_UP
Drug	Helveticoside [630-64-8]; Down 200; 7.4uM; PC3; HT_HG-U133A	DNAAF2 SIPA1L1 NAB2 PML	3.26e-04	188	40	4	3770_DN
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	DNAAF2 GON4L EML3 PML	3.33e-04	189	40	4	1168_DN
Drug	Methapyrilene hydrochloride [135-23-9]; Down 200; 13.4uM; PC3; HT_HG-U133A	UNC45A TRIO EML3 PML	3.46e-04	191	40	4	6644_DN
Drug	Naltrexone hydrochloride dihydrate [16676-29-2]; Up 200; 9.6uM; MCF7; HT_HG-U133A	APBA1 GON4L SIPA1L1 DNAH17	3.60e-04	193	40	4	2209_UP
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A	HABP4 UNC45A TRIO PML	3.60e-04	193	40	4	5922_UP
Drug	(+,-)-Octopamine hydrochloride [770-05-8]; Down 200; 21uM; PC3; HT_HG-U133A	NRG2 HABP4 TRIO EML3	3.60e-04	193	40	4	5050_DN
Drug	(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A	NRG2 TRIO SIPA1L1 NAB2	3.60e-04	193	40	4	4138_DN
Drug	Imipramine hydrochloride [113-52-0]; Down 200; 12.6uM; MCF7; HT_HG-U133A	ZNF131 EML3 SIPA1L1 NAB2	3.60e-04	193	40	4	5440_DN
Drug	Cefsulodin sodium salt [52152-93-9]; Down 200; 7.2uM; PC3; HT_HG-U133A	NRG2 TRIO DNAH17 PML	3.60e-04	193	40	4	4067_DN
Drug	Chlorpheniramine maleate [113-92-8]; Up 200; 10.2uM; PC3; HT_HG-U133A	APBA1 POU1F1 NAB2 PML	3.60e-04	193	40	4	2055_UP
Drug	Indapamide [26807-65-8]; Down 200; 10.6uM; PC3; HT_HG-U133A	TRIO EML3 NAB2 PML	3.67e-04	194	40	4	4335_DN
Drug	Primaquine diphosphate [63-45-6]; Down 200; 8.8uM; PC3; HT_HG-U133A	ARHGAP11A TRIO EML3 PML	3.67e-04	194	40	4	4263_DN
Drug	Estrone [53-16-7]; Up 200; 14.8uM; HL60; HT_HG-U133A	NRG2 SIPA1L1 DNAH17 PML	3.67e-04	194	40	4	3071_UP
Drug	Skimmianine [83-95-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A	DDX3Y TRIO NAB2 PML	3.67e-04	194	40	4	6066_UP
Drug	Erythromycin [114-07-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A	NRG2 HABP4 TRIO PML	3.75e-04	195	40	4	5329_UP
Drug	Ribostamycin sulfate salt [53797-35-6]; Down 200; 7.2uM; HL60; HT_HG-U133A	NRG2 UNC45A EML3 PML	3.75e-04	195	40	4	2705_DN
Drug	Betulinic acid [472-15-1]; Up 200; 8.8uM; HL60; HT_HG-U133A	GON4L EML3 NAB2 PML	3.75e-04	195	40	4	1345_UP
Drug	Azlocillin sodium salt [37091-65-9]; Down 200; 8.2uM; HL60; HT_HG-U133A	NRG2 SIPA1L1 NAB2 PML	3.75e-04	195	40	4	2727_DN
Drug	Oxalamine citrate salt [1949-20-8]; Up 200; 9.2uM; HL60; HT_HG-U133A	NRG2 HABP4 TRIO SIPA1L1	3.82e-04	196	40	4	3006_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	HABP4 UNC45A SIPA1L1 PML	3.82e-04	196	40	4	3872_DN
Drug	Norfloxacin [70458-96-7]; Down 200; 12.6uM; PC3; HT_HG-U133A	GON4L ARHGAP11A EML3 NAB2	3.82e-04	196	40	4	2090_DN
Drug	Bucladesine sodium salt [16980-89-5]; Up 200; 7.8uM; HL60; HT_HG-U133A	POU1F1 TRIO SIPA1L1 DNAH17	3.82e-04	196	40	4	2741_UP
Drug	Fluorocurarine chloride [22273-09-2]; Down 200; 11.6uM; HL60; HT_HG-U133A	ARHGAP11A EML3 SIPA1L1 PML	3.82e-04	196	40	4	2521_DN
Drug	Fluocinonide [356-12-7]; Down 200; 8uM; PC3; HT_HG-U133A	NRG2 HABP4 TRIO NAB2	3.82e-04	196	40	4	4314_DN
Drug	Adiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; HL60; HT_HG-U133A	RNF25 DNAAF2 ZNF131 EML3	3.82e-04	196	40	4	1872_UP
Drug	Isopropamide iodide [71-81-8]; Up 200; 8.4uM; HL60; HT_HG-U133A	DDX3Y PDE2A COL17A1 DNAH17	3.89e-04	197	40	4	2720_UP
Drug	genistein; Down 200; 10uM; PC3; HT_HG-U133A	NRG2 UNC45A NAB2 PML	3.89e-04	197	40	4	4459_DN
Drug	Mafenide hydrochloride [138-37-4]; Up 200; 18uM; MCF7; HT_HG-U133A	NRG2 TRIO NAB2 PML	3.89e-04	197	40	4	5499_UP
Drug	Iopanoic acid [96-83-3]; Up 200; 7uM; PC3; HT_HG-U133A	APBA1 TRIO DNAH17 NAB2	3.89e-04	197	40	4	6348_UP
Drug	Levopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; HL60; HT_HG-U133A	SIPA1L1 DNAH17 NAB2 PML	3.89e-04	197	40	4	2980_DN
Drug	chlorpromazine hydrochloride; Up 200; 1uM; PC3; HT_HG-U133A	TRIO EML3 NAB2 PML	3.89e-04	197	40	4	1217_UP
Drug	Vincamine [1617-90-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A	RNF25 TRIO SIPA1L1 PML	3.89e-04	197	40	4	3865_DN
Drug	Cefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; PC3; HT_HG-U133A	PDE2A TRIO NAB2 PML	3.89e-04	197	40	4	3686_UP
Drug	Guanadrel sulfate [22195-34-2]; Up 200; 7.6uM; PC3; HT_HG-U133A	DDX3Y UNC45A NAB2 PML	3.89e-04	197	40	4	3698_UP
Drug	Azathymine, 6 [932-53-6]; Up 200; 31.4uM; HL60; HT_HG-U133A	NRG2 PCSK2 SIPA1L1 PML	3.89e-04	197	40	4	2466_UP
Drug	Chlorzoxazone [95-25-0]; Down 200; 23.6uM; MCF7; HT_HG-U133A	HABP4 EML3 NAB2 PML	3.89e-04	197	40	4	2263_DN
Drug	Sulfathiazole [72-14-0]; Down 200; 15.6uM; MCF7; HT_HG-U133A	ZNF131 HABP4 ZNF22 NAB2	3.89e-04	197	40	4	1463_DN
Drug	Delsoline [509-18-2]; Up 200; 8.6uM; HL60; HT_HG-U133A	APBA1 POU1F1 COL17A1 PML	3.89e-04	197	40	4	2513_UP
Drug	Isoxsuprine hydrochloride [579-56-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A	ZNF22 EML3 SIPA1L1 PML	3.89e-04	197	40	4	1485_UP
Drug	DNA-PK Inhibitor III; Up 200; 1uM; MCF7; HT_HG-U133A	UNC45A ARHGAP11A NAB2 PML	3.97e-04	198	40	4	7513_UP
Drug	Nitrocaramiphen hydrochloride; Down 200; 10.8uM; MCF7; HT_HG-U133A	RNF25 HABP4 EML3 NAB2	3.97e-04	198	40	4	7464_DN
Drug	Ondansetron Hydrochloride [103639-04-9]; Up 200; 12.2uM; MCF7; HT_HG-U133A	APBA1 DDX3Y EML3 PML	3.97e-04	198	40	4	3575_UP
Drug	Urosiol [128-13-2]; Up 200; 10.2uM; PC3; HT_HG-U133A	NRG2 HABP4 UNC45A PML	3.97e-04	198	40	4	7243_UP
Drug	Azathymine, 6 [932-53-6]; Down 200; 31.4uM; PC3; HT_HG-U133A	UNC45A TRIO DNAH17 NAB2	3.97e-04	198	40	4	3987_DN
Drug	Triamterene [396-01-0]; Down 200; 15.8uM; PC3; HT_HG-U133A	NRG2 HABP4 UNC45A PML	3.97e-04	198	40	4	7307_DN
Drug	Glycocholic acid [475-31-0]; Up 200; 8.6uM; MCF7; HT_HG-U133A	RNF25 UNC45A NAB2 PML	3.97e-04	198	40	4	5316_UP
Drug	Ranitidine hydrochloride [66357-59-3]; Down 200; 11.4uM; MCF7; HT_HG-U133A	EML3 DNAH17 NAB2 PML	3.97e-04	198	40	4	2251_DN
Drug	Imipramine hydrochloride [113-52-0]; Down 200; 12.6uM; HL60; HT_HG-U133A	GON4L UNC45A EML3 PML	3.97e-04	198	40	4	1849_DN
Drug	Betahistine mesylate [54856-23-4]; Up 200; 17.2uM; HL60; HT_HG-U133A	UNC45A TRIO SIPA1L1 NAB2	3.97e-04	198	40	4	2472_UP
Drug	Deltaline [6836-11-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	APBA1 TRIO NAB2 PML	3.97e-04	198	40	4	3831_UP
Drug	Graveoline [485-61-0]; Up 200; 14.4uM; HL60; HT_HG-U133A	RNF25 PCSK2 COL17A1 NAB2	4.05e-04	199	40	4	2179_UP
Drug	Pramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; HL60; HT_HG-U133A	RNF25 DDX3Y SIPA1L1 NAB2	4.05e-04	199	40	4	2198_UP
Drug	rotenone; Up 200; 1uM; PC3; HT_HG-U133A	APBA1 HABP4 UNC45A TRIO	4.05e-04	199	40	4	5920_UP
Drug	Pizotifen malate [5189-11-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A	NRG2 EML3 DNAH17 NAB2	4.05e-04	199	40	4	6513_DN
Drug	Cefaclor [70356-03-5]; Up 200; 10.4uM; HL60; HT_HG-U133A	HABP4 TRIO NAB2 PML	4.05e-04	199	40	4	2483_UP
Drug	Zomepirac sodium salt [64092-48-4]; Down 200; 12.8uM; HL60; HT_HG-U133A	NRG2 EML3 NAB2 PML	4.05e-04	199	40	4	2713_DN
Drug	Cyclopentolate hydrochloride [5870-29-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A	ZNF22 EML3 NAB2 PML	4.05e-04	199	40	4	6214_UP
Drug	Dipivefrin hydrochloride [64019-93-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	GON4L SIPA1L1 NAB2 PML	4.05e-04	199	40	4	2744_DN
Drug	Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A	UNC45A EML3 SIPA1L1 NAB2	4.05e-04	199	40	4	2654_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; HL60; HT_HG-U133A	NRG2 DNAH17 NAB2 PML	4.05e-04	199	40	4	2205_UP
Drug	Prazosin hydrochloride [19237-84-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A	RNF25 NRG2 ARHGAP11A PML	4.05e-04	199	40	4	6475_DN
Drug	Mephenesin [59-47-2]; Up 200; 22uM; PC3; HT_HG-U133A	APBA1 PDE2A NAB2 PML	4.05e-04	199	40	4	3675_UP
Drug	fluphenazine dihydrochloride; Down 200; 10uM; SKMEL5; HG-U133A	GON4L SIPA1L1 NAB2 PML	4.05e-04	199	40	4	494_DN
Drug	Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; HL60; HT_HG-U133A	RNF25 DNAAF2 SIPA1L1 DNAH17	4.12e-04	200	40	4	2169_UP
Drug	Esculetin [305-01-1]; Down 200; 22.4uM; MCF7; HT_HG-U133A	RNF25 HABP4 ZNF22 SIPA1L1	4.12e-04	200	40	4	7459_DN
Disease	C-reactive protein measurement	EIF3C SETD5 EML3 IFT172 DNAH17 NUFIP2 SEPTIN2	7.77e-04	1206	38	7	EFO_0004458
Disease	insomnia measurement	PDE2A KMT5A NAB2 PML	2.47e-03	443	38	4	EFO_0007876
Disease	Neurodevelopmental Disorders	TRIO SETD5	6.42e-03	93	38	2	C1535926
Disease	intelligence, self reported educational attainment	APBA1 HABP4	9.98e-03	117	38	2	EFO_0004337, EFO_0004784
Disease	chronic lymphocytic leukemia	CCDC18 SEPTIN2	1.03e-02	119	38	2	EFO_0000095
Disease	Tinnitus	APBA1 SIPA1L1	1.22e-02	130	38	2	HP_0000360

Protein segments in the cluster

Peptide	Gene	Start	Entry
KGDKGDQVYAGRRRR	COL17A1	1476	Q9UMD9
KNRYKGGIREERARI	LEO1	591	Q8WVC0
GIYRKREEKRNAGNA	KMT5A	131	Q9NQR1
VDDGRGKAQFNKARR	DNAAF2	326	Q9NVR5
IYGRFDSKRREGKQL	NAB2	301	Q15742
RGKREFERYGGNDKI	HABP4	211	Q5JVS0
DQKGGAAYTDRDRKI	PDE2A	216	O00408
RDIRIKYGNGRKNSR	NRG2	281	O14511
EGLYKAFQRRAAKRR	FAM161B	376	Q96MY7
KELRNAGYEVRRKSG	H1-7	81	Q75WM6
QEEYEREATKKGARG	IFT172	1261	Q9UG01
RDQKDGYRKNEGYMR	EIF3C	886	Q99613
NKRYAAVRDAGVKIQ	DNAH17	826	Q9UFH2
GKRAERQRNEALYNA	CCDC18	231	Q5T9S5
KRKRDGRGQEGTLAY	GON4L	251	Q3T8J9
GGEAGQRYSKEKRDA	APBA1	331	Q02410
ERGKAAEFYSRGRKQ	LINC01560	11	Q8TB33
AYRGRQRGEKTKARA	C2orf81	371	A6NN90
AGGCKQLKNRYESRD	EML3	756	Q32P44
GEALKAVKENGRYGR	DDX3Y	246	O15523
MRYKRRGVDKNGNVA	INPP5F	291	Q9Y2H2
GQREKGYHEARKDQG	ARHGAP30	801	Q7Z6I6
YRARGRDDKGRKNMQ	KATNAL1	156	Q9BW62
GEYKRKRRQSVGDFV	ARHGAP11A	276	Q6P4F7
GALYNEKVGANERKR	POU1F1	201	P28069
AHRRDRQGGLKKYSR	PML	811	P29590
GERVRLKGFEKYRAQ	SIPA1L1	646	O43166
YRKRKQEAKENSAGG	SETD5	1071	Q9C0A6
IKGKEGRQAARNSDY	ATP11C	836	Q8NB49
GSAKEQRYQRGLERN	NUFIP2	636	Q7Z417
SDKEYQVNGKRVLGR	SEPTIN3	266	Q9UH03
EERKRLYQRQQERGG	RNF25	236	Q96BH1
KDRLVKENNYRGHGD	THOC3	86	Q96J01
KIYREGRGNESDYRK	SCLT1	431	Q96NL6
QGKAYENKRKTGRQR	ZNF22	16	P17026
YENFRSERLKRGGRK	SEPTIN2	296	Q15019
VVGDKNRARGCYRKA	TTC37	506	Q6PGP7
YRQGDRKGQIKEDGC	ZNF131	221	P52739
EKDGGDVKALYRRSQ	UNC45A	86	Q9H3U1
REGKLENGYRKSREG	TRIO	2651	O75962
QEGFDRKKRGYRDIN	PCSK2	101	P16519